Forcyte Biotechnologies, the biotech company that’s focused on single-cell contractility screening, has raised $1M in funding according to a recent SEC filing in what appears to be a convertible note. The total filing is for $2M and there was a total of three participants in the round. Forcyte was founded by Ivan Pushkarsky, Dino Di Carlo, and Robert Damoiseaux in 2017.
Page 4 of 4
